The DOI matches its Crossref record; 98 of the 98 references it cites were found in a registry or an index.
Statin-induced myopathy: a review and update
Abstract
INTRODUCTION: Statin-induced myopathy is an important cause of statin intolerance and the most common cause of statin discontinuation. Observational studies estimate that 10 - 15% of statin users develop statin-related muscle side effects ranging from mild myalgia to more severe muscle symptoms with significant CPK elevations. AREAS COVERED: This article reviews the epidemiology, clinical features, risk factors and mechanisms of statin-induced myopathy and provides an evidence-based algorithm for managing patients with statin myopathy. EXPERT OPINION: There are multiple risk factors for statin-induced myopathy that are both patient-related (age, genetics, co-morbidities) and drug-related (statin metabolism via the CYP system, drug-drug interactions and statin drug transport). Management options for statin-intolerant patients include statin switching, especially to low-dose, non-daily doses of long-acting statins, such as rosuvastatin and atorvastatin, and other non-statin lipid-lowering agents, such as ezetimibe and colesevelam, and possibly red yeast rice. In conclusion, statin-induced myopathy is a significant clinical problem that contributes considerably to statin therapy discontinuation. However, there exist multiple and effective management options for statin intolerant patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
SLCO1B1 Variants and Statin-Induced Myopathy — A Genomewide Study
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801936 · Cited by 2,043 · cited 2×
“Multiple studies have shown an association between SLCO1B1 polymorphisms and statin myopathy [40,41].”
BackgroundMethodThompson, P. D., Clarkson, P., & Karas, R. H. (2003) · JAMA · doi:10.1001/jama.289.13.1681 · Cited by 1,463
Bruckert, E., Hayem, G., Dejager, S., Yau, C., & Bégaud, B. (2005) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-005-5686-z · Cited by 1,226
ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins
Writing Committee Members:, Pasternak, R. C., Smith, S. C., Bairey-Merz, C. N., Grundy, S. M., Cleeman, J. I., & Lenfant, C. (2002) · Circulation · doi:10.1161/01.cir.0000032466.44170.44 · Cited by 1,088
The safety of statins in clinical practice
Armitage, J. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60716-8 · Cited by 833
Kotseva, K., Wood, D., Backer, G. D., Bacquer, D. D., Pyörälä, K., Keil, U., & EUROASPIRE Study Group (2009) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/hjr.0b013e3283294b1d · Cited by 812 · cited 1×
“A recent European study estimated that 20% of patients with coronary heart disease do not use statins [3].”
BackgroundStatin Safety: A Systematic Review
Law, M., & Rudnicka, A. R. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.12.010 · Cited by 808
A Novel Human Hepatic Organic Anion Transporting Polypeptide (OATP2)
Hsiang, B., Zhu, Y., Wang, Z., Wu, Y., Sasseville, V., Yang, W.-P., & Kirchgessner, T. G. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.52.37161 · Cited by 641
Cerivastatin and Reports of Fatal Rhabdomyolysis
Staffa, J. A., Chang, J., & Green, L. (2002) · New England Journal of Medicine · doi:10.1056/nejm200202143460721 · Cited by 626
Statin-associated myopathy with normal creatine kinase levels
Phillips, P. S., Haas, R. H., Bannykh, S., Hathaway, S., Gray, N. L., Kimura, B. J., Vladutiu, G. D., England, J. D. F., & and the Scripps Mercy Clinical Research Center* (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-7-200210010-00009 · Cited by 565
The Role of Coenzyme Q10 in Statin-Associated Myopathy
Marcoff, L., & Thompson, P. D. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.02.049 · Cited by 537
The SLCO1B1*5Genetic Variant Is Associated With Statin-Induced Side Effects
Voora, D., Shah, S. H., Spasojevic, I., Ali, S., Reed, C. R., Salisbury, B. A., & Ginsburg, G. S. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.04.053 · Cited by 502
Risks Associated With Statin Therapy: A Systematic Overview of Randomized Clinical Trials
Kashani, A., Phillips, C. O., Foody, J. M., Wang, Y., Mangalmurti, S., Ko, D. T., & Krumholz, H. M. (2006) · Circulation · doi:10.1161/circulationaha.106.624890 · Cited by 474
Narrative review: statin-related myopathy
Joy, T. R., & Hegele, R. A. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-12-200906160-00009 · Cited by 453
Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics of Atorvastatin and Rosuvastatin
Pasanen, M. K., Fredrikson, H., Neuvonen, P. J., & Niemi, M. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100220 · Cited by 432
McKenney, J. M., Davidson, M. H., Jacobson, T. A., & Guyton, J. R. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.02.030 · Cited by 431
Self-citationNiemi, M., Schaeffeler, E., Lang, T., Fromm, M. F., Neuvonen, M., Kyrklund, C., Backman, J. T., Kerb, R., Schwab, M., Neuvonen, P. J., et al. (2004) · Pharmacogenetics · doi:10.1097/01.fpc.0000114750.08559.32 · Cited by 418
Neuvonen, P. J., Kantola, T., & Kivistö, K. T. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90165-5 · Cited by 406
Guijarro, C., Blanco-Colio, L. M., Ortego, M., Alonso, C., Ortiz, A., Plaza, J. J., Díaz, C., Hernández, G., & Egido, J. (1998) · Circulation Research · doi:10.1161/01.res.83.5.490 · Cited by 390
Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin
Jones, P. H., & Davidson, M. H. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2004.08.076 · Cited by 387 · cited 1×
“The risk of rhabdomyolysis with gemfibrozil is much higher (10- to 15-fold) than that with fenofibrate because of differences in fibrate metabolism [65].”
BackgroundImmune‐mediated necrotizing myopathy associated with statins
Grable‐Esposito, P., Katzberg, H. D., Greenberg, S. A., Srinivasan, J., Katz, J., & Amato, A. A. (2010) · Muscle & Nerve · doi:10.1002/mus.21486 · Cited by 340
Transporter Pharmacogenetics and Statin Toxicity
Niemi, M. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.197 · Cited by 330
Effects of Fibrates on Metabolism of Statins in Human Hepatocytes
Prueksaritanont, T., Tang, C., Qiu, Y., Mu, L., Subramanian, R., & Lin, J. H. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.11.1280 · Cited by 325
Antidepressant-Induced Sexual Dysfunction
Gregorian, R. S., Golden, K. A., Bahce, A., Goodman, C., Kwong, W. J., & Khan, Z. M. (2002) · Annals of Pharmacotherapy · doi:10.1345/aph.1a195 · Cited by 320
Lu, Z., Kou, W., Du, B., Wu, Y., Zhao, S., Brusco, O. A., Morgan, J. M., & Capuzzi, D. M. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.02.056 · Cited by 315
McTaggart, S. J. (2006) · Cellular and Molecular Life Sciences CMLS · doi:10.1007/s00018-005-5298-6 · Cited by 293
The effect of gemfibrozil on the pharmacokinetics of rosuvastatin
Schneck, D. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.12.014 · Cited by 292
Current overview of statin-induced myopathy
Rosenson, R. S. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2003.10.033 · Cited by 287
Effect of Coenzyme Q10 on myopathic symptoms in patients treated with statins
Caso, G., Kelly, P., McNurlan, M. A., & Lawson, W. E. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.12.063 · Cited by 286
Statin-related adverse events: A meta-analysis
Silva, M. A., Swanson, A. C., Gandhi, P. J., & Tataronis, G. R. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.01.005 · Cited by 278
Red Yeast Rice for Dyslipidemia in Statin-Intolerant Patients: A Randomized Trial
Becker, D. J., Gordon, R. Y., Halbert, S. C., French, B., Morris, P. B., & Rader, D. J. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-12-200906160-00006 · Cited by 275
An Assessment of Statin Safety by Muscle Experts
Thompson, P. D., Clarkson, P. M., & Rosenson, R. S. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.12.013 · Cited by 259
Genetic risk factors associated with lipid-lowering drug-induced myopathies
Vladutiu, G. D., Simmons, Z., Isackson, P. J., Tarnopolsky, M., Peltier, W. L., Barboi, A. C., Sripathi, N., Wortmann, R. L., & Phillips, P. S. (2006) · Muscle & Nerve · doi:10.1002/mus.20567 · Cited by 253
Progressive myopathy with up-regulation of MHC-I associated with statin therapy
Needham, M., Fabian, V., Knezevic, W., Panegyres, P., Zilko, P., & Mastaglia, F. L. (2007) · Neuromuscular Disorders · doi:10.1016/j.nmd.2006.10.007 · Cited by 250
The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis
Harper, C. R., & Jacobson, T. A. (2007) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32825a6773 · Cited by 246
Self-citationStatin-induced apoptosis and skeletal myopathy
Dirks, A. J., & Jones, K. M. (2006) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00226.2006 · Cited by 240
Vaughan, C. J., & Gotto, A. M. (2004) · Circulation · doi:10.1161/01.cir.0000139312.10076.ba · Cited by 218
Statin-Induced Muscle Necrosis in the Rat: Distribution, Development, and Fibre Selectivity
Westwood, F. R., Bigley, A., Randall, K., Marsden, A. M., & Scott, R. C. (2005) · Toxicologic Pathology · doi:10.1080/01926230590908213 · Cited by 214
Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy
Silva, M., Matthews, M. L., Jarvis, C., Nolan, N. M., Belliveau, P., Malloy, M., & Gandhi, P. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.02.008 · Cited by 208
Managing Dyslipidemia in Chronic Kidney Disease
Harper, C. R., & Jacobson, T. A. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.03.025 · Cited by 204
Self-citationbenefit-risk assessment of Rosuvastatin 10 to 40 milligrams
Brewer, H. B. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00779-3 · Cited by 198
Statin Safety and Drug Interactions: Clinical Implications
Bottorff, M. B. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.12.007 · Cited by 188
Chatzizisis, Y. S., Koskinas, K. C., Misirli, G., Vaklavas, C., Hatzitolios, A., & Giannoglou, G. D. (2010) · Drug Safety · doi:10.2165/11319380-000000000-00000 · Cited by 187
Effect of coenzyme Q10 supplementation on simvastatin-induced myalgia
Young, J. M., Florkowski, C. M., Molyneux, S. L., McEwan, R. G., Frampton, C. M., George, P. M., & Scott, R. S. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.06.030 · Cited by 185
Ahmed, W., Khan, N., Glueck, C. J., Pandey, S., Wang, P., Goldenberg, N., Uppal, M., & Khanal, S. (2009) · Translational Research · doi:10.1016/j.trsl.2008.11.002 · Cited by 185
Laaksonen, R., Jokelainen, K., Sahi, T., Tikkanen, M. J., & Himberg, J.-J. (1995) · Clinical Pharmacology & Therapeutics · doi:10.1016/0009-9236(95)90266-x · Cited by 177 · cited 1×
“In addition, changes in myocyte CoQ10 levels in response to statins therapy have not been consistent in animal and human studies [26] and direct association between decreased intramuscular CoQ10 level Table 1.”
ResultNichols, G. A., & Koro, C. E. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.08.022 · Cited by 173
Toward “Pain-Free” Statin Prescribing: Clinical Algorithm for Diagnosis and Management of Myalgia
Jacobson, T. A. (2008) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)60897-5 · Cited by 168
Self-citationThe Efficacy and Six-Week Tolerability of Simvastatin 80 and 160 mg/Day
Davidson, M. H., Stein, E. A., Dujovne, C. A., Hunninghake, D. B., Weiss, S. R., Knopp, R. H., Illingworth, D. R., Mitchel, Y. B., Melino, M. R., Zupkis, R. V., et al. (1997) · The American Journal of Cardiology · doi:10.1016/s0002-9149(96)00742-4 · Cited by 167
Association between statin-associated myopathy and skeletal muscle damage
Mohaupt, M. G., Karas, R. H., Babiychuk, E. B., Sanchez-Freire, V., Monastyrskaya, K., Iyer, L., Hoppeler, H., Breil, F., & Draeger, A. (2009) · Canadian Medical Association Journal · doi:10.1503/cmaj.081785 · Cited by 166
Halbert, S. C., French, B., Gordon, R. Y., Farrar, J. T., Schmitz, K., Morris, P. B., Thompson, P. D., Rader, D. J., & Becker, D. J. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.08.672 · Cited by 154
Genetic determinants of statin intolerance
Oh, J., Ban, M. R., Miskie, B. A., Pollex, R. L., & Hegele, R. A. (2007) · Lipids in Health and Disease · doi:10.1186/1476-511x-6-7 · Cited by 154
Lovastatin, Nicotinic Acid, and Rhabdomyolysis
Reaven, P. D., & Witztum, J. L. (1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-109-7-597_2 · Cited by 152
Molecular clues into the pathogenesis of statin‐mediated muscle toxicity
Baker, S. K. (2005) · Muscle & Nerve · doi:10.1002/mus.20291 · Cited by 137
Backes, J. M., Venero, C. V., Gibson, C., Ruisinger, J. F., Howard, P. A., Thompson, P. D., & Moriarty, P. M. (2008) · Annals of Pharmacotherapy · doi:10.1345/aph.1k604 · Cited by 128
The genetics of statin-induced myopathy
Ghatak, A., Faheem, O., & Thompson, P. D. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.11.033 · Cited by 126
Molecular basis of statin-associated myopathy
Vaklavas, C., Chatzizisis, Y. S., Ziakas, A., Zamboulis, C., & Giannoglou, G. D. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.05.021 · Cited by 116
Statin safety: an appraisal from the adverse event reporting system
Davidson, M. H., Clark, J. A., Glass, L. M., & Kanumalla, A. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.12.008 · Cited by 113
Factors affecting patient compliance with antihyperlipidemic medications in an HMO population.
Sung, J. C., Nichol, M. B., Venturini, F., Bailey, K. L., McCombs, J. S., & Cody, M. (1998) · PubMed · Cited by 111
Statins as Immunomodulatory Agents
Mach, F. (2004) · Circulation · doi:10.1161/01.cir.0000129502.10459.fe · Cited by 110
Atherosclerosis: anti-inflammatory and immunomodulatory activities of statins
Kwak, B. R., Mulhaupt, F., & Mach, F. (2003) · Autoimmunity Reviews · doi:10.1016/s1568-9972(03)00049-1 · Cited by 105
Stein, E. A., Ballantyne, C. M., Windler, E., Sirnes, P. A., Sussekov, A., Yigit, Z., Seper, C., & Gimpelewicz, C. R. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.09.099 · Cited by 102 · cited 2×
“Only 3% discontinued the combination therapy while muscle-related side effects were reported in 24, 17 and 14% in ezetimibe, fluvastatin XL and combination therapy groups, respectively [79].”
BackgroundStatin myopathy: Incidence, risk factors, and pathophysiology
Sewright, K. A., Clarkson, P. M., & Thompson, P. D. (2007) · Current Atherosclerosis Reports · doi:10.1007/s11883-007-0050-3 · Cited by 101
Leiter, L. A., Bays, H. E., Conard, S. E., Bird, S. R., Rubino, J., Hanson, M. E., Tomassini, J. E., & Tershakovec, A. M. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.09.076 · Cited by 90
Approach to the Patient Who Is Intolerant of Statin Therapy
Eckel, R. H. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2689 · Cited by 88
Conard, S. E., Bays, H. E., Leiter, L. A., Bird, S. R., Rubino, J., Lowe, R. S., Tomassini, J. E., & Tershakovec, A. M. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.09.075 · Cited by 83
Myopathy with statin–fibrate combination therapy: clinical considerations
Jacobson, T. A. (2009) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.151 · Cited by 82 · cited 1×
“While gemfibrozil is an inhibitor of CYP2C8 and to a lesser extent, CYP2C9 and CYP3A4, fenofibrate and fenofibric acid undergo much less metabolism by the CYP system and are usually conjugated to glucuronides [69].”
BackgroundSelf-citationEzetimibe and Statin-Associated Myopathy
Fux, R., Mörike, K., Gundel, U.-F., Hartmann, R., & Gleiter, C. H. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-140-8-200404200-00034 · Cited by 80
Evidence-Based Management of Statin Myopathy
Harper, C. R., & Jacobson, T. A. (2010) · Current Atherosclerosis Reports · doi:10.1007/s11883-010-0120-9 · Cited by 79
Self-citationStatin myopathy: a review of recent progress
Mammen, A. L., & Amato, A. A. (2010) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e32833f0fc7 · Cited by 79
Gazi, I. F., Daskalopoulou, S. S., Nair, D. R., & Mikhailidis, D. P. (2007) · Current Medical Research and Opinion · doi:10.1185/030079907x226267 · Cited by 79
Efficacy of Rosuvastatin (5 mg and 10 mg) Twice a Week in Patients Intolerant to Daily Statins
Gadarla, M., Kearns, A. K., & Thompson, P. D. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.02.061 · Cited by 79
Nishimoto, T., Tozawa, R., Amano, Y., Wada, T., Imura, Y., & Sugiyama, Y. (2003) · Biochemical Pharmacology · doi:10.1016/j.bcp.2003.08.011 · Cited by 77
Comparative Effects of Fibrates on Drug Metabolizing Enzymes in Human Hepatocytes
Prueksaritanont, T., Richards, K. M., Qiu, Y., Strong-Basalyga, K., Miller, A. R., Li, C., Eisenhandler, R., & Carlini, E. J. (2005) · Pharmaceutical Research · doi:10.1007/s11095-004-9011-5 · Cited by 73
Glueck, C. J., Aregawi, D., Agloria, M., Khalil, Q., Winiarska, M., Munjal, J., Gogineni, S., & Wang, P. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.06.004 · Cited by 73
Athyros, V. G., Τζιόμαλος, Κ., Kakafika, A. I., Koumaras, H., Karagiannis, A. I., & Mikhailidis, D. P. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.09.096 · Cited by 71
Nakagomi, R., Nakai, D., & Tokui, T. (2007) · Xenobiotica · doi:10.1080/00498250601188808 · Cited by 70
Once-a-Week Rosuvastatin (2.5 to 20 mg) in Patients With a Previous Statin Intolerance
Ruisinger, J. F., Backes, J. M., Gibson, C., & Moriarty, P. M. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.09.095 · Cited by 67
Schoor, J. V. (2008) · Pharmacy management · Cited by 65
Amiodarone Interacts with Simvastatin but not with Pravastatin Disposition Kinetics
Becquemont, L., Neuvonen, M., Verstuyft, C., Jaillon, P., Letierce, A., Neuvonen, P. J., & Funck‐Brentano, C. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100098 · Cited by 64
Simard, C., & Poirier, P. (2006) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(06)70253-7 · Cited by 59
Backes, J. M., Moriarty, P. M., Ruisinger, J. F., & Gibson, C. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.03.059 · Cited by 57
Clinical characterization and molecular mechanisms of statin myopathy
Toth, P. P., Harper, C. R., & Jacobson, T. A. (2008) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.6.7.955 · Cited by 55 · cited 1×
“5 Autoimmune phenomena Autoimmune mechanisms for statin myopathy has been suggested previously [31].”
BackgroundSelf-citationEnhancement of Membrane Fluidity in Cholesterol-Poor Endothelial Cells Pre-treated with Simvastatin
Morita, I., Sato, I., Ma, L., & Murota, S. (1997) · Endothelium · doi:10.3109/10623329709079868 · Cited by 53
Goosen, T. C., Bauman, J. N., Davis, J. A., Yu, C., Hurst, S. I., Williams, J. A., & Loi, C. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.015230 · Cited by 53
Rivers, S. M., Kane, M. P., Busch, R. S., Bakst, G., & Hamilton, R. A. (2007) · Endocrine Practice · doi:10.4158/ep.13.1.11 · Cited by 50
Striated Muscle Safety of Ezetimibe/Simvastatin (Vytorin)
Davidson, M. H., Maccubbin, D., Stepanavage, M. E., Strony, J. T., & Musliner, T. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.08.038 · Cited by 46
Antiretroviral and Statin Drug-Drug Interactions
Ray, G. M. (2008) · Cardiology in Review · doi:10.1097/crd.0b013e3181903b7f · Cited by 41
Csako, G., McGriff, N. J., Rotman-Pikielny, P., Sarlis, N. J., & Pucino, F. (2001) · Annals of Pharmacotherapy · doi:10.1345/aph.1a031 · Cited by 40
Mackie, B. D., Satija, S., Nell‐Dybdahl, C., Miller, J. I., & Sperling, L. S. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.07.093 · Cited by 37
Asymptomatic hypothyroidism and statin-induced myopathy.
Bar, S. L., Holmes, D. T., & Frohlich, J. J. (2007) · Europe PMC (PubMed Central) · Cited by 37
Chatzizisis, Y. S., Jonas, M., Beigel, R., Coskun, A. U., Baker, A. B., Stone, B. V., Maynard, C. C., Gerrity, R. G., Daley, W. L., Edelman, E. R., et al. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.07.032 · Cited by 32
Safety of Niacin and Simvastatin Combination Therapy
Bays, H. E. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.02.026 · Cited by 32
Statin-Associated Myopathy with Normal Creatine Kinase Levels
Phillips, P. S., & Haas, R. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-12-200306170-00024 · Cited by 32
Red Yeast Rice for Dyslipidemia in Statin-Intolerant Patients
Becker, D. J., & Gordon, R. Y. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-152-2-201001190-00026 · Cited by 13
The tolerability and efficacy of low-dose simvastatin in statin-intolerant patients
Degreef, L. E., Opdam, F. L., Teepe‐Twiss, I. M., Jukema, J. W., Guchelaar, H., & Tamsma, J. T. (2010) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2010.03.015 · Cited by 12
Coenzyme Q10 Depletion: Etiopathogenic or Predisposing Factor in Statin Associated Myopathy?
Chatzizisis, Y. S., Vaklavas, C., & Giannoglou, G. D. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.12.005 · Cited by 11
Cited by
Guiding Principles for the Care of Older Adults with Multimorbidity: An Approach for Clinicians
American Geriatrics Society Expert Panel on the Care of Older Adults with Multimorbidity (2012) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2012.04188.x · Cited by 660
An assessment by the statin muscle safety task force: 2014 update
Rosenson, R. S., Baker, S. K., Jacobson, T. A., Kopecky, S. L., & Parker, B. A. (2014) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2014.03.004 · Cited by 485
Self-citationSafety and efficacy of statin therapy
Adhyaru, B. B., & Jacobson, T. A. (2018) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0098-5 · Cited by 424
Self-citationBanach, M., Rizzo, M., Toth, P. P., Farnier, M., Davidson, M. H., Al-Rasadi, K., Aronow, W. S., Athyros, V., Djuric, D. M., Ezhov, M. V., et al. (2015) · Archives of Medical Science · doi:10.5114/aoms.2015.49807 · Cited by 378
Wilke, R. A., Ramsey, L. B., Johnson, S. G., Maxwell, W. D., McLeod, H. L., Voora, D., Krauss, R. M., Roden, D. M., Feng, Q., Cooper-DeHoff, R. M., et al. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.57 · Cited by 332
Metadata
- Authors
- Abd, T. T., & Jacobson, T. A.
- Venue
- Expert Opinion on Drug Safety
- Publisher
- Informa Healthcare
- Published
- 2011-02-23
- Volume
- 10
- Issue
- 3
- Pages
- 373-387
- ISSN
- 1474-0338 (ISSN-L)
- 1744-764X
- OpenAlex
- W2136466059
- Cited by
- 322
- References
- 98
- FWCI
- 24.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.